293 related articles for article (PubMed ID: 20228428)
1. Management of chemotherapy-induced nausea and vomiting.
Dewan P; Singhal S; Harit D
Indian Pediatr; 2010 Feb; 47(2):149-55. PubMed ID: 20228428
[TBL] [Abstract][Full Text] [Related]
2. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
4. Patient-centered management of chemotherapy-induced nausea and vomiting.
Grunberg S
Cancer Control; 2012 Apr; 19(2 Suppl):10-5. PubMed ID: 22488023
[TBL] [Abstract][Full Text] [Related]
5. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
6. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
7. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Kottschade L; Novotny P; Lyss A; Mazurczak M; Loprinzi C; Barton D
Support Care Cancer; 2016 Jun; 24(6):2661-7. PubMed ID: 26768436
[TBL] [Abstract][Full Text] [Related]
9. [Nausea and vomiting after chemotherapy: an ongoing problem for patients].
Neefjes ECW; van der Vorst MJDL
Ned Tijdschr Geneeskd; 2023 May; 167():. PubMed ID: 37163378
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Schwartzberg LS
Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
[TBL] [Abstract][Full Text] [Related]
11. Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.
Vol H; Flank J; Lavoratore SR; Nathan PC; Taylor T; Zelunka E; Maloney AM; Lee Dupuis L
Support Care Cancer; 2016 Mar; 24(3):1365-71. PubMed ID: 26335406
[TBL] [Abstract][Full Text] [Related]
12. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
Aapro M; Molassiotis A; Dicato M; Peláez I; Rodríguez-Lescure Á; Pastorelli D; Ma L; Burke T; Gu A; Gascon P; Roila F;
Ann Oncol; 2012 Aug; 23(8):1986-1992. PubMed ID: 22396444
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
[TBL] [Abstract][Full Text] [Related]
14. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
15. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
Oo TH; Hesketh PJ
Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized trial of standard antiemetic therapy with yoga versus standard antiemetic therapy alone for highly emetogenic chemotherapy-induced nausea and vomiting in South Asian population.
Kothari TO; Jakhar SL; Bothra D; Sharma N; Kumar HS; Baradia MR
J Cancer Res Ther; 2019; 15(5):1120-1123. PubMed ID: 31603121
[TBL] [Abstract][Full Text] [Related]
17. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
Durand JP; Madelaine I; Scotté F
Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
19. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
20. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
